Astellas Pharma is focusing on diversification, with its portfolio spanning cancer, vision loss and menopause treatments. Its Chief Medical Officer, Tadaaki Taniguci, said the company was also expanding its gene therapy output, using acquisitions and licensing to build capability, while in oncology, the firm’s lead drugs include treatments for prostate and bladder cancer. Astellas is also testing a small molecule for treating menopause symptoms.
Sonatype reports rise in open source malware to 17,954
The 1Q 2025 Open Source Malware Index from Sonatype revealed that open source malware packages doubled compared to the same period last year, with 56%
